maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon Market Overview: GLP-1 Agonists and

These results give us a direction that GLP-1RAs, currently used for diabetes, may be an alternative drug for the treatment of osteoporosis

Natures GLP-1

To view or add a comment, sign in Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech by The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market

Although the cardiovascular safety of tirzepatide has been established in short-term trials [170], proof of beneficial effects on hard cardiovascular outcomes is still awaited with dedicated outcome trials ongoing (SURPASS-CVOT, NCT04255433

In 1929 they published a landmark review of ten investigations into the effect of secretin on blood glucose levels which had reported contradictory results